11,546 Shares in Medtronic PLC $MDT Bought by M Holdings Securities Inc.

M Holdings Securities Inc. purchased a new stake in shares of Medtronic PLC (NYSE:MDT) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 11,546 shares of the medical technology company’s stock, valued at approximately $995,000.

Other large investors have also added to or reduced their stakes in the company. Marshall Wace LLP boosted its holdings in shares of Medtronic by 3,424.7% during the second quarter. Marshall Wace LLP now owns 160,374 shares of the medical technology company’s stock worth $13,980,000 after purchasing an additional 155,824 shares during the period. Beutel Goodman & Co Ltd. raised its position in Medtronic by 2.4% during the 2nd quarter. Beutel Goodman & Co Ltd. now owns 4,907,266 shares of the medical technology company’s stock valued at $427,766,000 after purchasing an additional 115,209 shares during the last quarter. Dodge & Cox raised its position in Medtronic by 0.4% during the 2nd quarter. Dodge & Cox now owns 7,740,383 shares of the medical technology company’s stock valued at $674,729,000 after purchasing an additional 31,550 shares during the last quarter. Great Diamond Partners LLC purchased a new stake in Medtronic in the 2nd quarter worth approximately $446,000. Finally, Miramar Capital LLC grew its position in shares of Medtronic by 0.6% in the 2nd quarter. Miramar Capital LLC now owns 146,997 shares of the medical technology company’s stock worth $12,814,000 after buying an additional 903 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.0%

NYSE:MDT opened at $101.93 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm’s 50-day moving average price is $96.65 and its 200-day moving average price is $92.08. The company has a market capitalization of $130.68 billion, a PE ratio of 27.47, a P/E/G ratio of 2.69 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the company posted $1.26 EPS. Medtronic’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be paid a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. Medtronic’s dividend payout ratio is presently 76.55%.

Analysts Set New Price Targets

A number of brokerages recently commented on MDT. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. Daiwa Capital Markets upped their price objective on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Barclays raised their target price on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. Finally, Royal Bank Of Canada increased their price target on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and an average price target of $110.44.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.